ARNI Stock UPDATES Arno Therapeutics (ARNI) 1.3400 09/13/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arno Therapeutics (ARNI) 1.3400 $ARNI

Arno Therapeutics to Present at Upcoming Investor Conferences
GlobeNewswire - Mon Sep 08, 7:30AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Dr. Alex Zukiwski, Chief Executive Officer and Mr. Lawrence Kenyon, Chief Financial Officer, are scheduled to present at the 16 Annual Rodman & Renshaw Global Investment conference being held September 8-10, 2014 in New York and the Aegis Capital 2014 Healthcare & Technology Conference being held September 10-13, 2014 in Las Vegas.

Arno Therapeutics Reports Second Quarter 2014 Financial and Business Update
GlobeNewswire - Thu Aug 14, 3:49PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced financial results for the second quarter of 2014 and provided an update on recent clinical developments.

Arno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief Operating Officer
GlobeNewswire - Fri Jul 18, 3:30PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Alexander Zukiwski, M.D., has been appointed as the interim Chief Executive Officer effective immediately. Dr. Zukiwski will continue in his role as Vice President and Chief Medical Officer of the Company. Dr. Zukiwski has an extensive background in pharmaceuticals and biotechnology over a distinguished 19 year career, including serving as Executive Vice President, Clinical Research, and Chief Medical Officer at MedImmune, Inc., as well as positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD) and Ortho Biotech. Dr. Zukiwski replaces Mr. Glenn Mattes, who is leaving to pursue other opportunities.

Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones
GlobeNewswire - Tue Apr 01, 8:26AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced financial results for the full year ended December 31, 2013. For the year ended December 31, 2013, Arno reported a net loss of $39.7 million, or $5.28 per share, which includes $19.0 million related to non-cash interest expense from convertible debentures retired in 2013, $4.2 million of non-cash other expense for the increase in derivative liability of stock warrants, and $1.5 million of non-cash stock based compensation expense. Adjusting for these non-cash items, which totaled $24.7 million, the Company realized a net loss of $15.0 million on a non-GAAP basis, or $2.00 per share. This compares to full year 2012 net loss of $14.4 million, or $3.17 per share on a GAAP basis, and adjusted 2012 net loss of $10.2 million on a non-GAAP basis, or $2.25 per share, when considering the same non-cash adjustments.

Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014
GlobeNewswire - Wed Mar 26, 7:46AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new data from three research programs which support its investigational lead compound onapristone to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2014, being held April 5-9 in San Diego, California.

Arno Therapeutics Board of Directors Appoints Randy Thurman as Vice Chairman
GlobeNewswire - Mon Mar 24, 3:01PM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has appointed Randy H. Thurman as Vice Chairman of the Company's Board of Directors. Along with Arno's Chairman Dr. Arie Belldegrun, Mr. Thurman, who joined the Board in January 2013, will serve on the executive committee and work with the Company's leadership team to focus on the development of Arno's oncology pipeline, business development strategies and other key operational initiatives.

Arno Therapeutics to Present at 26th Annual ROTH Conference
GlobeNewswire - Wed Mar 05, 7:45AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Glenn Mattes is scheduled to present at the 26 Annual ROTH Conference, being held March 9-12, 2014 at the Ritz-Carlton, Laguna Niguel in Dana Point, CA.

Arno Therapeutics signs licensing agreement with University of Minnesota for use of oncology technology
M2 - Wed Mar 05, 5:44AM CST
US-based biopharmaceutical company Arno Therapeutics (Other OTC:ARNI) said on Tuesday that it has entered into an exclusive, worldwide license agreement with the University of Minnesota to investigate the gene expression signature derived from archived breast cancer tissue samples.

Arno Therapeutics Granted Exclusive License for Oncology Diagnostic Technique by University of Minnesota
GlobeNewswire - Tue Mar 04, 7:32AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has signed an exclusive, worldwide license agreement with the University of Minnesota for technology related to a gene expression signature derived from archived breast cancer tissue samples. This technique has the potential to identify progesterone-stimulated pathway activation and in turn, help identify patients who would most likely benefit from treatment with Arno's lead compound, onapristone, an anti-progestin therapeutic aimed at treatment of men's and women's cancers.

Arno Therapeutics names Lawrence A Kenyon as CFO
M2 - Fri Feb 28, 3:27AM CST
Biopharmaceutical company Arno Therapeutics (Other OTC:ARNI) revealed on Thursday the addition of Lawrence A Kenyon as its chief financial officer.

Arno Therapeutics Appoints Lawrence A. Kenyon Chief Financial Officer
GlobeNewswire - Thu Feb 27, 9:00AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has expanded its management team with the appointment of Lawrence A. Kenyon as Chief Financial Officer. Mr. Kenyon will report to President and Chief Executive Officer Glenn Mattes, and will direct financial reporting and controls. During a finance and accounting career spanning 25 years, Mr. Kenyon has spent over a decade leading the financial function at publicly-traded healthcare companies including several in the oncology space.

Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors
GlobeNewswire - Tue Jan 21, 11:06AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has enrolled the first patient in a Phase I dose escalation study evaluating onapristone in post-menopausal women with progesterone receptor (PR) positive tumors, including breast, endometrial and other solid tumors. The Phase I trial is designed to identify the recommended Phase II dose and determine the overall safety profile of onapristone.

Arno Therapeutics Expands Management Team With Additions of Two Scientific Leaders
GlobeNewswire - Mon Jan 13, 7:15AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has expanded its management team with the appointments of Joseph Bisaha, PhD as Vice President, Clinical Operations and Project Management and David M. Jackson, PhD as Vice President, Diagnostics. These additions to the Company's team of highly experienced and skilled members are expected to support the continued clinical development of Arno's lead compound and personalized therapy onapristone and the co-development of a companion diagnostic and other biomarkers with various partners and collaborators.

Arno Therapeutics to Present at Biotech Showcase 2014
GlobeNewswire - Thu Jan 09, 7:30AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that Chief Executive Officer Glenn Mattes is scheduled to present at Biotech Showcase(TM) 2014, taking place January 13-15, 2014 in San Francisco, Calif.

Arno Therapeutics Selects Leica Biosystems to Develop Companion Diagnostic for Targeted Oncology Therapy Onapristone
GlobeNewswire - Tue Jan 07, 7:15AM CST
Arno Therapeutics, Inc. (OTCQB:ARNI); (Arno), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, and Leica Biosystems (LBS), a global leader in pathology workflow solutions and automation, announced that the companies have entered into a co-development agreement for the development of a companion diagnostic (CDx) for Arno's lead compound and personalized therapy, onapristone.

Arno Therapeutics Inc submits IMPD to ANSM for planned Phase I trial of onapristone in PR positive tumors trial
M2 - Tue Sep 10, 8:59AM CDT
Biopharmaceutical company Arno Therapeutics Inc (OTC Markets:ARNI) revealed on Monday the submission of an Investigational Medicinal Product Dossier (IMPD) to request the clinical trial authorisation of a Phase I dose escalation study evaluating its lead compound onapristone in progesterone receptor positive tumors in post-menopausal women.

Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors
GlobeNewswire - Mon Sep 09, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced it has submitted an Investigational Medicinal Product Dossier (IMPD) to the French Health Authority, L'Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM), to request the clinical trial authorization of a Phase I dose escalation study evaluating Arno's lead compound onapristone in progesterone receptor positive tumors in post-menopausal women. Arno expects to initiate the Phase I trial in the fourth quarter of this year.

Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance
GlobeNewswire - Wed Aug 21, 8:06AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced it has initiated a pharmacokinetic (PK) study of onapristone. The initiation follows the submission and approval of an Investigational Medicinal Product Dossier (IMPD) by the French Health Authority, L'Agence Nationale de Securite du Medicament et des Produits de Sante (ANSM).

Arno Therapeutics to Collaborate With Veridex on Development of Diagnostic Test
GlobeNewswire - Mon Jun 03, 7:00AM CDT
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that it has signed an agreement with Veridex, LLC, a Johnson & Johnson company, to develop a diagnostic test to detect the presence of activated progesterone receptors (APRs) as a potential biomarker of anti-progestin activity in circulating tumor cells (CTCs). The diagnostic will help identify patients whom could potentially benefit from treatment with anti-progestins including onapristone, an orally-administered, investigational type 1 progestin receptor antagonist being developed by Arno.

Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
PR Newswire - Wed May 15, 5:00PM CDT
Arno Therapeutics, Inc. (OTCQB: ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced new, positive data from three studies supporting its investigational compound onapristone to be presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting, which is being held May 31-June 4, 2013 in Chicago, Illinois.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sunbit’s 2027 Loan Push Meets an NVIDIA-Fueled Tape

Updated Category News Views 143

Credit Is About to Enter Sunbit’s Growth Story Sunbit has spent years building a point-of-sale fintech footprint, and the numbers it cited on November 18 make the next step harder to dismiss as mere marketing fluff. The company says it has topped 400,000 activated cardholders and 50,000 merchants, while expecting more than $440 million in fiscal 2026 sales on greater...

Continue Reading
Subaru's 650-Car Anniversary Bet Is Delightfully Small

Updated Category News Views 31

Gold brake calipers may sound like a fussy correction, yet that little detail tells you exactly who Subaru is trying to please. The company has revised its announcement for the 2027 WRX tS GD25 and BRZ tS ZC15, clarifying the anniversary-model names and changing the WRX description from red-painted to gold-painted Brembo calipers. Nobody should confuse a corrected paint...

Continue Reading
Albany Masonry Waterproofing Is a Quiet Value Play

Updated Category News Views 92

Winter works its mischief one soaked brick at a time. That is the unglamorous truth behind Sean Mulligan's discussion of masonry waterproofing for Albany-area homes. Brick and stone look tough enough to outlast the furniture, the siding, maybe the whole neighborhood. Yet they are porous materials, and in a region where rain, snowmelt, and sharp temperature swings keep...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 81

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading
Italian Wine Faces U.S. Slump and New Market Openings

Updated Category News Views 110

American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 74

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 168

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 15

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 91

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 195

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading

Top 5 Most Recently Viewed Articles

New Leadership at KeyCorp: A Strategic Move for Risk Management

Updated Category News Views 304

KeyCorp Welcomes Mohit Ramani as Chief Risk Officer KeyCorp (NYSE: KEY), a prominent figure in the bank-based financial services industry, has made an important decision by announcing the appointment of Mohit (Mo) Ramani as its new Chief Risk Officer. This notable addition to the executive leadership team is seen as a strategic step towards enhancing the company's risk...

Continue Reading
Quaternary Ammonium Salts Market Expanding: Insights Ahead

Updated Category News Views 152

Exploring the Growth of the Quaternary Ammonium Salts Market The global quaternary ammonium salts market is on a remarkable growth trajectory, anticipated to reach a valuation of US$ 1,088.0 Million by the year 2034. With a robust CAGR of 5.9% from 2024 to 2034, this market is driven by increasing consumer awareness regarding hygiene and safety. Factors Driving Market...

Continue Reading
Generac's Upcoming Earnings: Key Details and Expectations

Updated Category News Views 147

Generac Prepares for Earnings Release and Conference Call Generac Holdings Inc. (NYSE: GNRC), known as a prominent leader in energy technology solutions, is gearing up for an important announcement. The company plans to unveil its fourth quarter and full-year 2024 financial results just before the market opens. The anticipated date for this release is set for an upcoming...

Continue Reading
AAVantgarde Ready for Key Presentations at EURetina 2025

Updated Category News Views 207

Significant Presentation at EURetina 2025 AAVantgarde Bio, a leading clinical-stage biotechnology company, is poised to present updated outcomes from its LUCE-1 clinical trial at the prestigious 25th European Society of Retina Specialists (EURETINA) Annual Congress in Paris. This event, scheduled from September 4-7, 2025, offers a vital platform for advancing discussions...

Continue Reading
Investing in WisdomTree Funds: Insights on Value and Performance

Updated Category News Views 246

Understanding the Value of WisdomTree Funds WisdomTree is known for its innovative approach to exchange-traded funds (ETFs). As investors seek ways to maximize their asset portfolios, understanding the net asset values (NAVs) of these funds becomes essential. In this article, we delve into various funds offered by WisdomTree, highlighting their date of valuation and key...

Continue Reading